Publications by authors named "Christopher Venner"

Claim this Profile
R
Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database.
Julia Varghese, Christopher P Venner, Martha Louzada, Donna Reece, Darrell White

Clin Lymphoma Myeloma Leuk· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of the Central Nervous System International Prognostic Index in patients with primary mediastinal large B-cell lymphoma treated with rituximab-containing chemoimmunotherapy.
Jiayu Yang, Anna R Hayden, Diego Villa, Aixiang Jiang, Alina S Gerrie, Christopher P Venner

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with R-CHOP-like Therapy in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma.
Jean-Nicolas Champagne, Diego Villa, Alina S Gerrie, Christopher P Venner, Graham W Slack

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database.
Rayan Kaedbey, Christopher P Venner, Donna Reece, Kevin Hay, Engin Gul

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis.
Arleigh McCurdy, Engin Gul, Donna Reece, Michael P Chu, Victor H Jimenez-Zepeda, Christopher P Venner

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.
Hira S Mian, Alissa Visram, Steven Chun-Min Shih, Suzanne Trudel, Annette E Hay, Christopher P Venner

Clin Lymphoma Myeloma Leuk· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Saad Z Usmani, Thierry Facon, Vania Hungria, Nizar J Bahlis, Christopher P Venner

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Thierry Facon, Philippe Moreau, Katja Weisel, Hartmut Goldschmidt, Saad Z Usmani, Christopher P Venner

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Philippe Moreau, Thierry Facon, Saad Z Usmani, Nizar Bahlis, Noopur Raje, Christopher P Venner

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the clinical trial efficacy real-world effectiveness of treatments for multiple myeloma: a population-based study.
Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky, Christopher Venner

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Mohammad S Ebraheem, Rajshekhar Chakraborty, Bram Rochwerg, Alissa Visram, Ghulam Rehman Mohyuddin, Christopher P Venner

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone.
Yi Xu, Belinda A Campbell, Matthew Chan, Jessica Chan, Pedro Farinha, Christopher P Venner

Clin Transl Radiat Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.
Mégane Tanguay, Jean Roy, Jiandong Su, Engin Gul, Donna Reece, Christopher P Venner

Cancer Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.
Christopher P Venner, Peter Duggan, Kevin Song, Donna Reece, Smriti Sharma

Transplant Cell Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database.
Rayan Kaedbey, Donna Reece, Christopher P Venner, Arleigh McCurdy, Jiandong Su

EJHaem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience.
Hanbo Zhang, Nimira S Alimohamed, Naveen S Basappa, Tina Cheng, Michael Chu, Christopher P Venner, Peter Venner

Can Urol Assoc J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis.
Jowon Laura Kim, Alina S Gerrie, Kerry Joane Savage, Diego Villa, David Scott, Christopher Venner

Leuk Lymphoma· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resolution of Cardiac Infiltration Following Autologous Stem Cell Transplantation for AL Amyloidosis.
Kai Yi Wu, Craig R Butler, Nowell M Fine, Christopher Venner, D Ian Paterson

JACC Case Rep· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
Richard LeBlanc, Hira Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Christopher Venner

Eur J Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD negativity: considerations for older adults with multiple myeloma.
Hira Mian, Tanya M Wildes, Christopher P Venner, Rafael Fonseca

Blood Cancer J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database.
Julie Côté, Richard LeBlanc, Hira Mian, Michael P Chu, Arleigh McCurdy, Christopher P Venner

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.
Arleigh McCurdy, Hira Mian, Richard LeBlanc, Victor H Jimenez-Zepeda, Jiandong Su, Christopher P Venner

Blood Cancer J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis